NONMYELOABLATIVE PREPARATIVE REGIMEN USING MYLOTARG FOR PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA (AML), ACUTE LYMPHOCYTIC LEUKEMIA (ALL), CHRONIC MYELOID LEUKEMIA (CML) AND MYELODYSPLASTIC SYNDROME (MDS):